Deciphering E-Pharmacy Discounts For Novartis’s Ceritinib In India
Executive Summary
Novartis’s anticancer Spexib was being offered at a hefty 69% discount to patients in India, highlighting what some experts suggest is the striking pricing structure and business practices at e-pharmacies in the country.
You may also be interested in...
Natco Blocked Over Indian Oncology Duo
Novartis gains upper hand for now, staving off challenge to patents on its oncology drugs ribociclib and ceritinib in India by seasoned opponent Natco, though things appear far from over in the case.
Twin Gains For Novartis In India Ribociclib, Ceritinib Patent Cases
Novartis gains upper hand for now, staving off challenge to patents on its oncology drugs ribociclib and ceritinib in India by seasoned opponent Natco, though things appear far from over in the case.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.